S100A1 DNA-based Inotropic Therapy Protects Against Proarrhythmogenic Ryanodine Receptor 2 Dysfunction

Molecular Therapy

Volumn 23, Issue 8, 2015, Pages 1320-1330

  Ritterhoff, Julia ^a   Völkers, Mirko ^a   Seitz, Andreas ^a   Spaich, Kristin ^a   Gao, Erhe ^b   Peppel, Karsten ^c   Pleger, Sven T ^a   Zimmermann, Wolfram H ^d,e   Friedrich, Oliver ^f   Fink, Rainer H A ^a   Koch, Walter J ^b   Katus, Hugo A ^a,e   Most, Patrick ^a,c,e,g  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^e DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^f UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^g UNIQURE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BETA ADRENERGIC RECEPTOR; CALCIUM BINDING PROTEIN; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CALCIUM ION; CALMODULIN; COMPLEMENTARY DNA; CYCLIC AMP DEPENDENT PROTEIN KINASE; PARVOVIRUS VECTOR; RYANODINE RECEPTOR 2; S100A1 PROTEIN; SORCIN; UNCLASSIFIED DRUG; CALCIUM; FK 506 BINDING PROTEIN; PROTEIN BINDING; PROTEIN S 100; RYANODINE RECEPTOR; RYANODINE RECEPTOR 2. MOUSE; SRI PROTEIN, MOUSE; TACROLIMUS BINDING PROTEIN 1B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CONTROLLED STUDY; DIASTOLE; HEART CONTRACTION; HEART FAILURE; HEART FIBRILLATION; HEART INFARCTION; HEART MUSCLE CELL; HEART PROARRHYTHMIA; IN VITRO STUDY; IN VIVO STUDY; INOTROPISM; MALE; MOUSE; NONHUMAN; PROTEIN DEFECT; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RAT; SARCOPLASMIC RETICULUM; STOICHIOMETRY; TISSUE ENGINEERING; VIRAL GENE DELIVERY SYSTEM; ANIMAL; CARDIAC MUSCLE; CARDIAC MUSCLE CELL; CYTOLOGY; ELECTROCARDIOGRAPHY; FLUORESCENCE MICROSCOPY; GENE TRANSFER; GENETICS; METABOLISM; PHOSPHORYLATION; PROCEDURES; SPRAGUE DAWLEY RAT;

ANIMALS; CALCIUM; CALCIUM-BINDING PROTEINS; CALMODULIN; DNA, COMPLEMENTARY; ELECTROCARDIOGRAPHY; GENE TRANSFER TECHNIQUES; HEART FAILURE; MALE; MICE; MICROSCOPY, FLUORESCENCE; MYOCARDIUM; MYOCYTES, CARDIAC; PHOSPHORYLATION; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; S100 PROTEINS; SARCOPLASMIC RETICULUM; TACROLIMUS BINDING PROTEINS; TISSUE ENGINEERING;

EID: 84938416960     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2015.93     Document Type: Article

References (45)

1. Bers, DM (2002). Cardiac excitation-contraction coupling. Nature 415: 198-205.
2. Bers, DM (2014). Cardiac sarcoplasmic reticulum calcium leak: basis and roles in cardiac dysfunction. Annu Rev Physiol 76: 107-127.
3. Morgan, J P, Erny, RE, Allen, PD, Grossman, W and Gwathmey, JK (1990). Abnormal intracellular calcium handling, a major cause of systolic and diastolic dysfunction in ventricular myocardium from patients with heart failure. Circulation 81(2 Suppl): III21-III32.
4. Farr, MA and Basson, CT (2004). Sparking the failing heart. N Engl J Med 351: 185-187.
5. Katz, AM (1986). Potential deleterious effects of inotropic agents in the therapy of chronic heart failure. Circulation 73(3 Pt 2): III184-III190.
6. Overgaard, CB and Dzavík, V (2008). Inotropes and vasopressors: review of physiology and clinical use in cardiovascular disease. Circulation 118: 1047-1056.
7. Eisner, DA, Kashimura, T, Venetucci, LA and Trafford, AW (2009). From the ryanodine receptor to cardiac arrhythmias. Circ J 73: 1561-1567.
8. Venetucci, LA, Trafford, AW and Eisner, DA (2007). Increasing ryanodine receptor open probability alone does not produce arrhythmogenic calcium waves: threshold sarcoplasmic reticulum calcium content is required. Circ Res 100: 105-111.
9. Pogwizd, SM, Schlotthauer, K, Li, L, Yuan, W and Bers, DM (2001). Arrhythmogenesis and contractile dysfunction in heart failure: Roles of sodium-calcium exchange, inward rectifer potassium current, and residual beta-adrenergic responsiveness. Circ Res 88: 1159-1167.
10. Marx, SO and Marks, AR (2013). Dysfunctional ryanodine receptors in the heart: new insights into complex cardiovascular diseases. J Mol Cell Cardiol 58: 225-231.
11. George, CH, Jundi, H, Thomas, NL, Fry, DL and Lai, FA (2007). Ryanodine receptors and ventricular arrhythmias: emerging trends in mutations, mechanisms and therapies. J Mol Cell Cardiol 42: 34-50.
12. Ter Keurs, HE and Boyden, PA (2007). Calcium and arrhythmogenesis. Physiol Rev 87: 457-506.
13. Eisner, DA, Kashimura, T, O'Neill, SC, Venetucci, LA and Trafford, AW (2009). What role does modulation of the ryanodine receptor play in cardiac inotropy and arrhythmogenesis? J Mol Cell Cardiol 46: 474-481.
14. Venetucci, LA, Trafford, AW, O'Neill, SC and Eisner, DA (2008). The sarcoplasmic reticulum and arrhythmogenic calcium release. Cardiovasc Res 77: 285-292.
15. Pleger, S T, Brinks, H, Ritterhoff, J, Raake, P, Koch, WJ, Katus, HA et al. (2013). Heart failure gene therapy: the path to clinical practice. Circ Res 113: 792-809.
16. Ritterhoff, J and Most, P (2012). Targeting S100A1 in heart failure. Gene Ther 19: 613-621.
17. Rohde, D, Ritterhoff, J, Voelkers, M, Katus, HA, Parker, TG and Most, P (2010). S100A1: a multifaceted therapeutic target in cardiovascular disease. J Cardiovasc Transl Res 3: 525-537.
18. Brinks, H, Rohde, D, Voelkers, M, Qiu, G, Pleger, ST, Herzog, N et al. (2011). S100A1 genetically targeted therapy reverses dysfunction of human failing cardiomyocytes. J Am Coll Cardiol 58: 966-973.
19. Most, P, Seifert, H, Gao, E, Funakoshi, H, Völkers, M, Heierhorst, J et al. (2006). Cardiac S100A1 protein levels determine contractile performance and propensity toward heart failure after myocardial infarction. Circulation 114: 1258-1268.
20. Most, P, Pleger, ST, Völkers, M, Heidt, B, Boerries, M, Weichenhan, D et al. (2004). Cardiac adenoviral S100A1 gene delivery rescues failing myocardium. J Clin Invest 114: 1550-1563.
21. Remppis, A, Greten, T, Schäfer, BW, Hunziker, P, Erne, P, Katus, HA et al. (1996). Altered expression of the Ca(2+)-binding protein S100A1 in human cardiomyopathy. Biochim Biophys Acta 1313: 253-257.
22. Pleger, ST, Most, P, Boucher, M, Soltys, S, Chuprun, JK, Pleger, W et al. (2007). Stable myocardial-specifc AAV6-S100A1 gene therapy results in chronic functional heart failure rescue. Circulation 115: 2506-2515.
23. Pleger, S T, Shan, C, Ksienzyk, J, Bekeredjian, R, Boekstegers, P, Hinkel, R et al. (2011). Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model. Sci Transl Med 3: 92ra64.
24. Pleger, ST, Kziencek, J, Mueller, O, Bekeredjian, R, Remppis, A (2008). Retroinfusion-facilitated inotropic AAV9-S100A1 gene therapy restores global cardiac function in a clinically relevant pig heart failure model. Circulation 118: S-792.
25. Pleger, ST, Remppis, A, Heidt, B, Völkers, M, Chuprun, JK, Kuhn, M et al. (2005). S100A1 gene therapy preserves in vivo cardiac function after myocardial infarction. Mol Ther 12: 1120-1129.
26. Kettlewell, S, Most, P, Currie, S, Koch, WJ and Smith, GL (2005). S100A1 increases the gain of excitation-contraction coupling in isolated rabbit ventricular cardiomyocytes. J Mol Cell Cardiol 39: 900-910.
27. Most, P, Boerries, M, Eicher, C, Schweda, C, Völkers, M, Wedel, T et al. (2005). Distinct subcellular location of the Ca2+-binding protein S100A1 differentially modulates Ca2+-cycling in ventricular rat cardiomyocytes. J Cell Sci 118(Pt 2): 421-431.
28. Most, P, Remppis, A, Pleger, ST, Löffer, E, Ehlermann, P, Bernotat, J et al. (2003). Transgenic overexpression of the Ca2+-binding protein S100A1 in the heart leads to increased in vivo myocardial contractile performance. J Biol Chem 278: 33809-33817.
29. Völkers, M, Loughrey, CM, Macquaide, N, Remppis, A, DeGeorge, BR Jr, Wegner, FV et al. (2007). S100A1 decreases calcium spark frequency and alters their spatial characteristics in permeabilized adult ventricular cardiomyocytes. Cell Calcium 41: 135-143.
30. Yamaguchi, N, Chakraborty, A, Huang, TQ, Xu, L, Gomez, AC, Pasek, DA et al. (2013). Cardiac hypertrophy associated with impaired regulation of cardiac ryanodine receptor by calmodulin and S100A1. Am J Physiol Heart Circ Physiol 305: H86-H94.
31. Marx, SO, Reiken, S, Hisamatsu, Y, Jayaraman, T, Burkhoff, D, Rosemblit, N et al. (2000). PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell 101: 365-376.
32. Györke, I and Györke, S (1998). Regulation of the cardiac ryanodine receptor channel by luminal Ca2+ involves luminal Ca2+ sensing sites. Biophys J 75: 2801-2810.
33. Cheng, H and Lederer, WJ (2008). Calcium sparks. Physiol Rev 88: 1491-1545.
34. Lampe, PD and Lau, AF (2004). The effects of connexin phosphorylation on gap junctional communication. Int J Biochem Cell Biol 36: 1171-1186.
35. Farrell, EF, Antaramian, A, Rueda, A, Gómez, AM and Valdivia, HH (2003). Sorcin inhibits calcium release and modulates excitation-contraction coupling in the heart. J Biol Chem 278: 34660-34666.
36. Xu, L and Meissner, G (2004). Mechanism of calmodulin inhibition of cardiac sarcoplasmic reticulum Ca2+ release channel (ryanodine receptor). Biophys J 86: 797-804.
37. Völkers, M, Weidenhammer, C, Herzog, N, Qiu, G, Spaich, K, von Wegner, F et al. (2011). The inotropic peptide ßARKct improves ßAR responsiveness in normal and failing cardiomyocytes through G(ß?)-mediated L-type calcium current disinhibition. Circ Res 108: 27-39.
38. Weber, C, Neacsu, I, Krautz, B, Schlegel, P, Sauer, S, Raake, P et al. (2014). Therapeutic safety of high myocardial expression levels of the molecular inotrope S100A1 in a preclinical heart failure model. Gene Ther 21: 131-138.
39. Tsuda, T, Gao, E, Evangelisti, L, Markova, D, Ma, X and Chu, ML (2003). Post-ischemic myocardial fbrosis occurs independent of hemodynamic changes. Cardiovasc Res 59: 926-933.
40. Müller, OJ, Schinkel, S, Kleinschmidt, JA, Katus, HA and Bekeredjian, R (2008). Augmentation of AAV-mediated cardiac gene transfer after systemic administration in adult rats. Gene Ther 15: 1558-1565.
41. Mitchell, GF, Jeron, A and Koren, G (1998). Measurement of heart rate and Q-T interval in the conscious mouse. Am J Physiol 274(3 Pt 2): H747-H751.
42. Most, P, Bernotat, J, Ehlermann, P, Pleger, ST, Reppel, M, Börries, M et al. (2001). S100A1: a regulator of myocardial contractility. Proc Natl Acad Sci USA 98: 13889-13894.
43. Cheng, H, Song, LS, Shirokova, N, González, A, Lakatta, EG, Ríos, E et al. (1999). Amplitude distribution of calcium sparks in confocal images: theory and studies with an automatic detection method. Biophys J 76: 606-617.
44. Zimmermann, WH, Schneiderbanger, K, Schubert, P, Didié, M, Münzel, F, Heubach, JF et al. (2002). Tissue engineering of a differentiated cardiac muscle construct. Circ Res 90: 223-230.
45. Tiburcy, M, Didié, M, Boy, O, Christalla, P, Döker, S, Naito, H et al. (2011). Terminal differentiation, advanced organotypic maturation, and modeling of hypertrophic growth in engineered heart tissue. Circ Res 109: 1105-1114.